Lung Cancer Clinical Trials in New York, NY

322 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer	Phase 3	NRG Oncology	<1 mi
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer	Phase 2/3	SWOG Cancer Research Network	<1 mi
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer	Phase 3	National Cancer Institute (NCI)	<1 mi
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer	Phase 3	University of Texas Southwestern Medical Center	<1 mi
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC	Phase 2	Eikon Therapeutics	<1 mi
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer	Phase 3	Daiichi Sankyo	<1 mi
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain	Phase 3	NRG Oncology	<1 mi
S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer	Phase 3	SWOG Cancer Research Network	<1 mi
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection	—	Alliance for Clinical Trials in Oncology	<1 mi
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial	Phase 2/3	National Cancer Institute (NCI)	<1 mi
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer	Phase 1/2	Memorial Sloan Kettering Cancer Center	<1 mi
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer	Phase 1/2	National Cancer Institute (NCI)	<1 mi
Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung Cancer	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and Chest	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
Using Urine Samples to Identify Lung Cancer	—	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Lung Cancer Screening in People With Unexplained Weight Loss	—	Memorial Sloan Kettering Cancer Center	<1 mi
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of ZEN003694 in People With Squamous Cell Lung Cancer	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.	Phase 1	Pfizer	<1 mi
A Study of Sacituzumab Govitecan in People With Mesothelioma	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors	Phase 1	Pfizer	<1 mi
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Hospital-at-Home for People Receiving Tarlatamab	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma	Phase 1	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma	Phase 1	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)	Phase 2	SWOG Cancer Research Network	<1 mi
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer	Phase 1	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer	—	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer	Phase 1	Memorial Sloan Kettering Cancer Center	<1 mi
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial	Phase 3	NRG Oncology	<1 mi
A Registry for People With Lung Cancer	—	Memorial Sloan Kettering Cancer Center	<1 mi
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Sotorasib in People With Non-Small Cell Lung Cancer	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)	Phase 3	Merck Sharp & Dohme LLC	<1 mi
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1	Phase 3	Summit Therapeutics	<1 mi
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)	Phase 2	Memorial Sloan Kettering Cancer Center	<1 mi
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation	—	Guardant Health, Inc.	<1 mi
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)	Phase 1/2	Daiichi Sankyo	<1 mi
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors	Phase 1	Exelixis	<1 mi
Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients	—	PrECOG, LLC.	<1 mi
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation	Phase 1	AstraZeneca	<1 mi
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 2	Janssen Research & Development, LLC	<1 mi
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)	Phase 3	Shanghai Junshi Bioscience Co., Ltd.	<1 mi
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment	Phase 3	AstraZeneca	<1 mi
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors	Phase 1	SystImmune Inc.	<1 mi
A Phase 1/1b Study of IAM1363 in HER2 Cancers	Phase 1	Iambic Therapeutics, Inc	<1 mi
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion	Phase 1	Bristol-Myers Squibb	<1 mi
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements	Phase 1/2	Turning Point Therapeutics, Inc.	<1 mi
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma	Phase 3	Children's Oncology Group	<1 mi
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers	Phase 1	Tizona Therapeutics, Inc	<1 mi
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry	—	Massive Bio, Inc.	<1 mi
Evaluating the Implementation of a Comprehensive Multilevel Virtual Oncology Program Among Veterans Diagnosed With Lung, Colorectal, Prostate, and Breast Cancers in the US Department of Veterans Affairs	—	NYU Langone Health	<1 mi
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor	Phase 3	OSE Immunotherapeutics	<1 mi
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer	Phase 3	AstraZeneca	<1 mi
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer	Phase 3	Eli Lilly and Company	<1 mi
Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation	Phase 2	Mirati Therapeutics Inc.	<1 mi
A Study of Sigvotatug Vedotin in Advanced Solid Tumors	Phase 1	Seagen, a wholly owned subsidiary of Pfizer	<1 mi
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies	Phase 1/2	Ascendis Pharma Oncology Division A/S	<1 mi
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors	Phase 1	Cogent Biosciences, Inc.	<1 mi
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors	Phase 1/2	Revolution Medicines, Inc.	<1 mi
Inpatient Capture: A Mixed Methods Study to Develop an Inpatient Lung Cancer Screening Program in a Safety Net Hospital.	N/A	Physician Affiliate Group of New York	<1 mi
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC	Phase 1	AstraZeneca	<1 mi
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors	Phase 2	Iovance Biotherapeutics, Inc.	<1 mi
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC	Phase 3	NovoCure GmbH	<1 mi
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer	Phase 1/2	Janssen Research & Development, LLC	<1 mi
Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers	—	Scientific Institute San Raffaele	<1 mi
Daratumumab in STK11 Mutated NSCLC	Phase 2	NYU Langone Health	<1 mi
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment	Phase 3	Boehringer Ingelheim	<1 mi
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression	Phase 1/2	A2 Biotherapeutics Inc.	<1 mi
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies	Phase 1	Janux Therapeutics	<1 mi
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations	Phase 1	Alterome Therapeutics, Inc.	<1 mi
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors	Phase 1	Eli Lilly and Company	<1 mi
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors	Phase 1/2	Bristol-Myers Squibb	<1 mi
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC	Phase 3	Nuvalent Inc.	<1 mi
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors	Phase 1	Eli Lilly and Company	<1 mi
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer	Phase 1	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	<1 mi
BBO-11818 in Adult Subjects With KRAS Mutant Cancer	Phase 1	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	<1 mi
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC	Phase 1/2	Tubulis GmbH	<1 mi
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors	Phase 1	Innate Pharma	<1 mi
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors	Phase 1/2	Verastem, Inc.	<1 mi
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)	Phase 1	Boehringer Ingelheim	<1 mi
Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers	—	Lung Cancer Mutation Consortium	<1 mi
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer	Phase 2	Iovance Biotherapeutics, Inc.	<1 mi
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas	Phase 1/2	Novartis Pharmaceuticals	<1 mi
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer	Phase 1/2	IDEAYA Biosciences	<1 mi
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies	Phase 1/2	Institut de Recherches Internationales Servier	<1 mi
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies	Phase 1/2	AstraZeneca	<1 mi
Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC	Phase 2	Weill Medical College of Cornell University	<1 mi
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)	—	Merck Sharp & Dohme LLC	<1 mi
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer	Phase 1/2	BioNTech SE	<1 mi
Phase II Trial of Lung Chemoemobolization	Phase 2	City of Hope Medical Center	<1 mi
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors	Phase 1	Aktis Oncology, Inc.	<1 mi
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation	Phase 1	Incyte Corporation	<1 mi
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)	Phase 1/2	Merck Sharp & Dohme LLC	<1 mi
Safety and Efficacy of OBX-115 in Advanced Solid Tumors	Phase 1/2	Obsidian Therapeutics, Inc.	<1 mi
Pembrolizumab for Advanced NSCLC and PS 2-3	Phase 2	Icahn School of Medicine at Mount Sinai	<1 mi
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)	Phase 2	Genentech, Inc.	<1 mi
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders	Phase 2	Carl Allen	<1 mi
A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors	Phase 1	Eli Lilly and Company	<1 mi
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy Following Chemoimmunotherapy	Phase 2	BioNTech SE	<1 mi
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab	Phase 1/2	Linnaeus Therapeutics, Inc.	<1 mi
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia	—	University of Rochester	<1 mi
AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).	Phase 1	Amgen	<1 mi
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%	Phase 3	Bristol-Myers Squibb	<1 mi
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors	Phase 1/2	Marengo Therapeutics, Inc.	<1 mi
Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®	Phase 2	CivaTech Oncology	<1 mi
Patient-Generated Health Data Collection During Chemoradiotherapy for Lung Cancer	—	The New York Proton Center	<1 mi
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer	Phase 3	Eli Lilly and Company	<1 mi
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors	Phase 1	Calico Life Sciences LLC	<1 mi
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors	Phase 1	Revolution Medicines, Inc.	<1 mi
DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer	Phase 2	NYU Langone Health	<1 mi
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression	Phase 1/2	A2 Biotherapeutics Inc.	<1 mi
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)	Phase 2/3	Bristol-Myers Squibb	<1 mi
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)	Phase 3	Revolution Medicines, Inc.	<1 mi
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer	Phase 1	BeiGene	<1 mi
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer	Phase 1	Avistone Biotechnology Co., Ltd.	<1 mi
A Study of Mental Health Care in People With Cancer	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection	Phase 3	Taiho Oncology, Inc.	<1 mi
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types	Phase 1/2	Eisai Inc.	<1 mi
Empathic Communication Skills (ECS) Training	N/A	Memorial Sloan Kettering Cancer Center	<1 mi
Confocal Laser Endomicroscopy VERification	N/A	Amsterdam University Medical Centers (UMC), Location Academic Medical Center (AMC)	<1 mi
Multilevel Intervention for Precision Oncology	N/A	VA Office of Research and Development	<1 mi
DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer	Phase 1	Legend Biotech USA Inc	<1 mi
GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2	Phase 1	Y-mAbs Therapeutics	<1 mi
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation	Phase 1/2	Arvinas Inc.	<1 mi
Longitudinal Evaluation of Microbial and Host Signatures During Immunotherapy for Lung Cancer	—	NYU Langone Health	<1 mi
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)	Phase 3	Amgen	<1 mi
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors	Phase 1/2	BioNTech SE	<1 mi
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients	Phase 1/2	Tango Therapeutics, Inc.	<1 mi
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors	Phase 1	Bicara Therapeutics	<1 mi
A Study of JNJ-86974680 in Participants With Advanced Non-small Cell Lung Cancer	Phase 1	Johnson & Johnson Enterprise Innovation Inc.	<1 mi
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors	Phase 1	Eli Lilly and Company	<1 mi
A Study of LY4175408 in Participants With Advanced Cancer	Phase 1	Eli Lilly and Company	<1 mi
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer	Phase 1	Daiichi Sankyo	<1 mi
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing	—	A2 Biotherapeutics Inc.	<1 mi
PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56	Phase 1/2	Memorial Sloan Kettering Cancer Center	<1 mi
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer	Phase 1/2	Iovance Biotherapeutics, Inc.	<1 mi
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors	Phase 1	Astellas Pharma Inc	<1 mi
Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities	Phase 1/2	Taiho Pharmaceutical Co., Ltd.	<1 mi
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers	Phase 2	Boehringer Ingelheim	<1 mi
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC	Phase 1/2	Icahn School of Medicine at Mount Sinai	<1 mi
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)	Phase 3	Nuvation Bio Inc.	<1 mi
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation	Phase 1/2	Hoffmann-La Roche	<1 mi
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors	Phase 1/2	Tango Therapeutics, Inc.	<1 mi
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS	Phase 3	AstraZeneca	<1 mi
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients	Phase 3	Summit Therapeutics	<1 mi
Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer	Phase 3	Canadian Cancer Trials Group	<1 mi
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers	Phase 1/2	Synthekine	<1 mi
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation	Phase 1	Clasp Therapeutics, Inc.	<1 mi
Study of DF1001 in Patients with Advanced Solid Tumors	Phase 1/2	Dragonfly Therapeutics	<1 mi
Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)	—	Oncology Center of Biochemical Education And Research	<1 mi
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC	Phase 2	Teligene US	<1 mi
A Long-term Extension Study of PCI-32765 (Ibrutinib)	Phase 3	Janssen Research & Development, LLC	<1 mi
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)	Phase 1	Tr1X, Inc.	<1 mi
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations	Phase 1/2	Daiichi Sankyo	<1 mi
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors	Phase 1	SystImmune Inc.	<1 mi
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)	Phase 1/2	Eli Lilly and Company	<1 mi
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2	Phase 1	Mersana Therapeutics	<1 mi
National Cancer Institute "Cancer Moonshot Biobank"	—	National Cancer Institute (NCI)	<1 mi
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer	Phase 1/2	Regeneron Pharmaceuticals	<1 mi
A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study	—	Invenio Imaging Inc.	<1 mi
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)	Phase 3	Merck Sharp & Dohme LLC	<1 mi
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors	Phase 1	SystImmune Inc.	<1 mi
Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability	Phase 3	NRG Oncology	<1 mi
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma	Phase 1/2	VM Oncology, LLC	<1 mi
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study	N/A	AIDS Malignancy Consortium	<1 mi
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss	Phase 1/2	Tango Therapeutics, Inc.	<1 mi
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC	Phase 1/2	Revolution Medicines, Inc.	<1 mi
Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation	Phase 1/2	RedCloud Bio	<1 mi
Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer	—	Washington University School of Medicine	<1 mi
GEMINI-NSCLC: NSCLC Biomarker Study	—	Tempus AI	<1 mi
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors	Phase 2	Daiichi Sankyo	<1 mi
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)	Phase 3	Amgen	<1 mi
GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors	Phase 1/2	GI Innovation, Inc.	<1 mi
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations	Phase 3	ArriVent BioPharma, Inc.	<1 mi
Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy	Phase 1	Abdera Therapeutics Inc.	<1 mi
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors	Phase 1	IDEAYA Biosciences	<1 mi
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer	Phase 1/2	Volastra Therapeutics, Inc.	<1 mi
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS	Phase 1/2	Revolution Medicines, Inc.	<1 mi
Lung Cancer Biomarkers and Screening	—	NYU Langone Health	<1 mi
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion	Phase 1	IDEAYA Biosciences	<1 mi
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors	Phase 1	Eli Lilly and Company	<1 mi
Study of Oral MRT-2359 in Selected Cancer Patients	Phase 1/2	Monte Rosa Therapeutics, Inc	<1 mi
WTC Chest CT Imaging Archive	—	Icahn School of Medicine at Mount Sinai	<1 mi
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors	Phase 1	Eli Lilly and Company	<1 mi
Ladarixin With Sotorasib in Advanced NSCLC	Phase 1	NYU Langone Health	<1 mi
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors	Phase 1	EMD Serono Research & Development Institute, Inc.	<1 mi
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation	Phase 2	M.D. Anderson Cancer Center	<1 mi
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors	Phase 1	Plexium, Inc.	<1 mi
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)	Phase 1/2	PMV Pharmaceuticals, Inc	<1 mi
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies	Phase 1	TopAlliance Biosciences	<1 mi
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)	Phase 2	Johnson & Johnson Enterprise Innovation Inc.	<1 mi
First in Human Study of AZD9592 in Solid Tumors	Phase 1	AstraZeneca	<1 mi
Comprehensive Outcomes for After Cancer Health	N/A	Pack Health	<1 mi
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors	Phase 1	AstraZeneca	<1 mi
Study of DF6215 in Patients with Advanced Solid Tumors	Phase 1	Dragonfly Therapeutics	<1 mi
A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)	Phase 1	Dizal Pharmaceuticals	<1 mi
A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors	Phase 1/2	Bayer	<1 mi
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer	Phase 1	Ankyra Therapeutics, Inc	<1 mi
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 3	AstraZeneca	<1 mi
A Study of BMS-986504 in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)	Phase 2	Bristol-Myers Squibb	<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses	Phase 2	Reunion Neuroscience Inc	<1 mi
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies	Phase 1/2	GV20 Therapeutics	<1 mi
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors	Phase 1	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	<1 mi
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)	Phase 1	AbbVie	<1 mi
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors	Phase 2	DualityBio Inc.	<1 mi
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma	Phase 1	Nammi Therapeutics Inc	<1 mi
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors	Phase 1/2	DualityBio Inc.	<1 mi
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy	Phase 3	Pierre Fabre Medicament	<1 mi
Brodalumab in the Treatment of Immune-Related Adverse Events	Phase 1	Brian Henick, MD	<1 mi
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors	Phase 1	BeOne Medicines	<1 mi
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors	Phase 1/2	DualityBio Inc.	<1 mi
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.	Phase 2	Taiho Oncology, Inc.	4 mi
ATATcH Alternating Treatment Plans for Advanced Cancer	Phase 2	Rutgers, The State University of New Jersey	4 mi
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer	Phase 2	National Cancer Institute (NCI)	4 mi
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Phase 3	AbbVie	5 mi
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])	Phase 3	National Cancer Institute (NCI)	5 mi
Leveraging the Emergency Department (LEAD) Study	N/A	Hackensack Meridian Health	6 mi
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7	Phase 2/3	Mirati Therapeutics Inc.	9 mi
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics	—	Wake Forest University Health Sciences	11 mi
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer	Phase 3	AstraZeneca	11 mi
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer	Phase 3	Alliance for Clinical Trials in Oncology	12 mi
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations	Phase 3	Daiichi Sankyo	12 mi
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial	Phase 3	National Cancer Institute (NCI)	12 mi
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT	—	The Radiosurgery Society	12 mi
Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors	Phase 1	Radiopharm Theranostics, Ltd	12 mi
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Phase 2	AbbVie	12 mi
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)	Phase 2	SWOG Cancer Research Network	12 mi
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)	Phase 2/3	SWOG Cancer Research Network	12 mi
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy	N/A	Wake Forest University Health Sciences	12 mi
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer	Phase 3	Hoffmann-La Roche	12 mi
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment	Phase 3	Boehringer Ingelheim	12 mi
A Study of DF6002 Alone and in Combination With Nivolumab	Phase 1	Dragonfly Therapeutics	12 mi
Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients	Phase 2	National Cancer Institute (NCI)	12 mi
Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer	Phase 1	National Cancer Institute (NCI)	12 mi
Cough Capture as a Portal Into the Lung	—	Albert Einstein College of Medicine	12 mi
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial	Phase 3	National Cancer Institute (NCI)	12 mi
EXoPERT EMERALD Clinical Study	—	EXoPERT	12 mi
Centralized Screening Unit (CSU) at Montefiore-Einstein	N/A	Albert Einstein College of Medicine	12 mi
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer	Phase 2	Nitin Ohri	12 mi
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy	Phase 2	Hackensack Meridian Health	12 mi
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer	Phase 2	Janssen Research & Development, LLC	12 mi
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma	Phase 1	Pfizer	12 mi
Iscador® P (Mistletoe) Immunotherapy for Recurrent Osteogenic Sarcoma	Phase 2	Hackensack Meridian Health	12 mi
Anti-CD38 Antibody With KRAS Vaccine and Anti-PD-1 Antibody in Subjects With Pancreatic Ductal Adenocarcinoma and Refractory Non-Small Cell Lung Cancer	Phase 2	Georgetown University	12 mi
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer	Phase 1	Zai Lab (Shanghai) Co., Ltd.	12 mi
Support for Cancer Patients Awaiting News	N/A	Hackensack Meridian Health	12 mi
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors	Phase 1/2	Alentis Therapeutics AG	12 mi
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors	Phase 1/2	Alentis Therapeutics AG	12 mi
CT-95 in Advanced Cancers Associated With Mesothelin Expression	Phase 1	Context Therapeutics Inc.	12 mi
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.	Phase 1	Bristol-Myers Squibb	12 mi
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)	Phase 1/2	Merck Sharp & Dohme LLC	12 mi
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)	Phase 1	Astellas Pharma Global Development, Inc.	12 mi
A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors	Phase 1/2	Bristol-Myers Squibb	12 mi
A Phase 1 Study of LNCB74 in Advanced Solid Tumors	Phase 1	NextCure, Inc.	12 mi
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors	Phase 1	NiKang Therapeutics, Inc.	12 mi
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors	Phase 1/2	Bristol-Myers Squibb	12 mi
Post-operative Urinary Retention (POUR) Following Thoracic Surgery	Phase 1/2	Hackensack Meridian Health	12 mi
RAPA-201 Therapy of Solid Tumors	Phase 1/2	Rapa Therapeutics LLC	12 mi
Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform	—	Elephas	12 mi
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)	Phase 3	Merck Sharp & Dohme LLC	13 mi
Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study	—	Tempus AI	13 mi
STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers	Phase 1/2	STORM Therapeutics LTD	16 mi
IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)	Phase 2	Innate Pharma	16 mi
A Study of MGC026 in Participants With Advanced Solid Tumors	Phase 1	MacroGenics	16 mi
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer	Phase 2/3	BioNTech SE	16 mi
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib	Phase 1/2	Genprex, Inc.	16 mi
A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)	Phase 2	Merck Sharp & Dohme LLC	16 mi
A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)	Phase 3	Bayer	17 mi
Virtual Personalized Exercise Program for Lung Cancer Patients	N/A	Northwell Health	17 mi
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors	Phase 1/2	Astellas Pharma Global Development, Inc.	17 mi
Collection of Sputum and Labeling for Lung Cancer	—	bioAffinity Technologies Inc.	19 mi
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC	Phase 3	AstraZeneca	21 mi
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib	Phase 2	Janssen Research & Development, LLC	22 mi
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer	Phase 2	BicycleTx Limited	22 mi
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)	Phase 3	AstraZeneca	22 mi
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer	Phase 3	Daiichi Sankyo	22 mi
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC	Phase 3	AstraZeneca	22 mi
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)	Phase 2	Regeneron Pharmaceuticals	26 mi
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)	Phase 3	Merck Sharp & Dohme LLC	26 mi
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)	Phase 3	Merck Sharp & Dohme LLC	26 mi
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer	Phase 3	BioNTech SE	26 mi
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change	Phase 2	National Cancer Institute (NCI)	26 mi
BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)	Phase 2	SCRI Development Innovations, LLC	26 mi
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)	Phase 3	Mirati Therapeutics Inc.	26 mi
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)	Phase 3	Pfizer	26 mi
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.	Phase 3	Pfizer	27 mi
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 3	Pfizer	27 mi
Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC	Phase 1/2	Xencor, Inc.	27 mi
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma	Phase 3	AstraZeneca	28 mi
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer	Phase 1	Christian Hinrichs	28 mi
Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy	—	Bo Lu	28 mi
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors	Phase 1	Kura Oncology, Inc.	28 mi
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm	Phase 2	Greg Durm, MD	28 mi
TELESCOPE- TELEhealth Shared Decision-making COaching	N/A	Rutgers, The State University of New Jersey	28 mi
Adaptive Radiation Planning for the Reduction of Radiation-Induced Toxicity in Patients With Stage II-IV Non-small Cell Lung Cancer	N/A	Rutgers, The State University of New Jersey	28 mi
TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics	N/A	Rutgers, The State University of New Jersey	28 mi
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors	Phase 1/2	MBrace Therapeutics	29 mi
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations	Phase 1/2	AbbVie	29 mi
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer	Phase 2/3	AbbVie	29 mi
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)	Phase 3	Merck Sharp & Dohme LLC	29 mi
ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors	Phase 3	OncoC4, Inc.	29 mi
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors	Phase 1	BeiGene	29 mi
Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer	Phase 1/2	Yale University	29 mi
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion	Phase 2/3	Bristol-Myers Squibb	29 mi
Liquid Biopsy Based NGS in Newly Diagnosed NSCLC	N/A	Charu Aggarwal	30 mi
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)	Phase 2	SWOG Cancer Research Network	30 mi
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations	Phase 3	AstraZeneca	30 mi
Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier	—	Veracyte, Inc.	34 mi
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening	—	Freenome Holdings Inc.	34 mi
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)	Phase 3	Merck Sharp & Dohme LLC	34 mi
Definitive Radiation for High-Risk Spine Metastases	Phase 2	Stony Brook University	48 mi
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Phase 2/3	AbbVie	48 mi
SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors	N/A	Barbara Nemesure	48 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.